Pills masthead

News Releases

Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011

201020092008200720062004

Aug 26, 2020
Financial and Business Highlights:

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 fourth quarter and full year ended June 30, 2020. "For both the fiscal 2020 full year and fourth quarter, our...

More
Aug 19, 2020

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 fourth quarter and full year on Wednesday, August 26, 2020, after the market closes....

More
Aug 17, 2020

Lannett Company, Inc. (NYSE: LCI) today announced the Notice of Proposed Settlement and Dismissal with Prejudice of Derivative Action (the "Notice"), a copy of which is attached hereto as an...

More
Aug 17, 2020
--Company Extends Distribution Term for Generic ADVAIR DISKUS®--

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone...

More
Aug 3, 2020

Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and...

More
Jul 27, 2020
-- Signs Exclusive U.S. Distribution Agreement with Novitium Pharma --

Lannett Company, Inc. (NYSE: LCI) today announced that it will soon launch Levorphanol Tablets 2 mg, a partnered product. Lannett entered into an exclusive U.S. distribution agreement for...

More
Jul 23, 2020
--Second Product with Strategic Partner, Rivopharm--

Lannett Company, Inc. (NYSE: LCI) today announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the...

More
Jul 16, 2020
--Lannett to Commence Marketing on August 3, 2020--

Lannett Company, Inc. (NYSE: LCI) and Cediprof, Inc., a part of the Neolpharma Pharmaceutical Group family of companies, today said that the companies have entered into an interim exclusive supply...

More
Jul 13, 2020

Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost savings plan. The initiatives include consolidating the research and development (R&D) function into a single location in...

More
Jun 11, 2020
--Company Anticipates Biosimilar Application to be Submitted By End of Calendar Year 2022--

Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration (FDA) on the clinical advancement...

More
 
Price Data
NYSELCI